Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed

Pluristem to Deliver Two Presentations During Israel's Largest Biotech
Conference: IATI-BioMed

HAIFA, Israel, June 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that Pluristem's CEO and its Project Innovation
Research Manager will be delivering two different presentations during
Israel's largest biotechnology conference, the 12^th Annual IATI-BioMed
Conference June 10^th through 12^th, 2013 in Tel Aviv.

Zami Aberman, Pluristem's Chairman and CEO, has been invited to speak at a
satellite symposium on June 11^th entitled "Haifa -Life sciences: innovation
and excellence at its best". Mr. Aberman will present details of the company,
as Pluristem exemplifies the type of success story in the life sciences
created at Haifa's MATAM Advanced Technology Park. Accompanying Mr. Aberman to
the podium will be Mr. Yona Yahav, Mayor of the City of Haifa and Professor
Dan Shechtman, Nobel Laureate in Chemistry, Technion - Israel Institute of
Technology, who will be the keynote speaker.

Additionally, on June 11^th, Eytan Abraham PhD, Project Innovation Research
Manager at Pluristem, will give a lecture entitled "Systemic Therapeutic
Effect of Placental Expanded Cells (PLX) Following Local Administration in
Hind Limb Ischemia Model," and will present data illustrating that the local
intramuscular (IM) administration of PLX-PAD cells can produce a systemic
effect in this animal model.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss that local
intramuscular (IM) administration of PLX-PAD cells can produce a systemic
effect in this animal model we are using forward-looking statements. These
forward-looking statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo